Use of a csrnpi inhibitor in the preparation of a medicament for the treatment of liver ischemia reperfusion injury

By designing CSRNP1 inhibitors to interfere with CSRNP1 gene expression and inhibit the MAPK pathway, the problem of effective treatment for hepatic ischemia-reperfusion injury was solved, significantly reducing hepatocyte apoptosis and providing a new molecular mechanism for the treatment of HIRI.

CN117281906BActive Publication Date: 2026-06-26ZHEJIANG UNIV
0 Cites 0 Cited by

Patent Information

Application Number
CN202311350004.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-10-18
Publication Date
2026-06-26
Estimated Expiration
2043-10-18

AI Technical Summary

Technical Problem

Current technologies lack effective drugs to prevent or treat liver ischemia-reperfusion injury (HIRI), especially given the high incidence of early graft dysfunction (EAD) after liver transplantation and the worsening situation when using extended standard donors (ECD). The role of altered CSRNP1 gene expression in HIRI remains unclear.

Method used

We designed siRNA and shRNA targeting the CSRNP1 gene as CSRNP1 inhibitors. By inhibiting the expression or activity of the CSRNP1 gene, we interfered with the MAPK pathway, especially the phosphorylation of SAPK, and reduced hepatocyte apoptosis.

Benefits of technology

It significantly reduces hepatocyte apoptosis after hypoxia-reoxygenation, alleviates HIRI, provides a new molecular mechanism for the treatment of HIRI, and offers a new strategy for clinical treatment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The application provides application of a CSRNP1 inhibitor in preparation of a medicine for treating liver ischemia-reperfusion injury. The application further clarifies a molecular mechanism in which CSRNP1 improves hepatocyte injury by targeting a MAPK signaling pathway mediated cell apoptosis in the process of ischemia-reperfusion, and provides a new treatment strategy for reducing ischemia-reperfusion injury in a liver surgery process, by deeply analyzing expression changes of CSRNP1 in the process of liver ischemia-reperfusion and correlation between the expression changes and ischemia-reperfusion injury caused by a liver surgery.
Need to check novelty before this filing date? Find Prior Art